Larimar Therapeutics Q3 2024 GAAP EPS $(0.24) Beats $(0.39) Estimate. Cash and Equivalents $203.7M
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics reported a Q3 2024 GAAP EPS of $(0.24), beating the analyst estimate of $(0.39). The company has $203.7M in cash and equivalents.
October 30, 2024 | 11:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Larimar Therapeutics reported a better-than-expected Q3 2024 EPS of $(0.24), surpassing the consensus estimate of $(0.39). The company also holds $203.7M in cash and equivalents.
The better-than-expected EPS indicates stronger financial performance than anticipated, which is likely to positively impact the stock price in the short term. The substantial cash reserves further strengthen the company's financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100